Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amgen, Inc. (AMGN) vs Star Bulk Carriers Corp (SBLK) Price & Performance

Amgen, Inc.Trade
Star Bulk Carriers CorpTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs Star Bulk Carriers Corp — how do they compare? Amgen, Inc. trades at $414.85 (market cap $224.14B), while Star Bulk Carriers Corp trades at $27.75 (market cap $3.09B). The key difference: Amgen, Inc. is far larger — about 72.5× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays the higher dividend (6.79%). Which is the better fit depends on your goals.

AMGNSBLK
Market Cap
$224.14B$3.09B
Sector
HealthIndustrials
52-Week High
$417.20$29.15
52-Week Low
$271.18$16.79
Enterprise Value
$267.45B$3.77B
Dividend Yield
2.43%6.79%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amgen, Inc.

Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.

Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.

Star Bulk Carriers Corp

Star Bulk Carriers (SBLK) trades at $27.80, down 2.18% on the day, with a bullish technical signal from moving averages and strong quarterly earnings beats. The company reported robust Q2 2026 results with net income of $144.9 million and declared a $0.90 dividend, reflecting operational strength. Revenue grew to $1.2 billion in 2026, with net profit margin expanding to 23.86%, while valuation ratios like P/E of 10.85 and EV/EBITDA of 7.46 suggest reasonable pricing. Recent news highlights termination of a vessel agreement with Diana Shipping, but operational updates remain positive.

SBLK presents a favorable outlook with earnings momentum, high dividend yield, and analyst buy consensus, though risks include dry bulk rate volatility and competitive pressures. The stock's fundamental health supports potential upside, but investors should weigh cyclical industry exposure against strong cash flow generation and balance sheet flexibility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN

About Star Bulk Carriers Corp

Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.

Read more on SBLK